Sanofi ADR (SNY)vsWipro Limited ADR (WIT)
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
WIT
Wipro Limited ADR
$1.95
-1.52%
TECHNOLOGY · Cap: $20.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Wipro Limited ADR generates 1856% more annual revenue ($926.24B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 14.2%. WIT appears more attractively valued with a PEG of 1.29. WIT earns a higher WallStSmart Score of 59/100 (C).
SNY
Buy51
out of 100
Grade: C-
WIT
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.0%
Fair Value
$62.70
Current Price
$43.31
$19.39 discount
Intrinsic value data unavailable for WIT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Generating 26.9B in free cash flow
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Weak financial health signals
Earnings declined 1.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bull Case : WIT
The strongest argument for WIT centers on Free Cash Flow, Altman Z-Score, P/E Ratio. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Bear Case : WIT
The primary concerns for WIT are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
SNY profiles as a mature stock while WIT is a value play — different risk/reward profiles.
WIT carries more volatility with a beta of 0.37 — expect wider price swings.
WIT is growing revenue faster at 7.7% — sustainability is the question.
WIT generates stronger free cash flow (26.9B), providing more financial flexibility.
Bottom Line
WIT scores higher overall (59/100 vs 51/100). SNY offers better value entry with a 25.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Wipro Limited ADR
TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA
Wipro Limited is a global information technology (IT), consulting and business process services company. The company is headquartered in Bengaluru, India.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?